Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6239673 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL5875849 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL179966 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL304332 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| Hydrochloric Acid SCHEMBL27564569 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL27564565 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL21013404 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL4602665 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL2616362 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTRAB9ANPC1KMT2A | |
| SCHEMBL20911243 | 0.79 | ALDH1A1 (0.76) | ALDH1A1MAPTRAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116731006-B | Thiazole aminoguanidine compound as well as preparation method and application thereof | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2024-04-02 | — | — | CN | claimed |
| CN-116731006-A | Thiazole aminoguanidine compound as well as preparation method and application thereof | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2023-09-12 | — | — | CN | claimed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| JP-2006504796-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | claimed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | claimed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | claimed |
| CN-1440402-A | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | CN | claimed |
| EP-1296978-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-02 | — | — | EP | claimed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | claimed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | claimed |
| EP-4610262-A1 | MACROCYCLIC COMPOUND AS CDK9 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12297222-B2 | CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-4016152-A | SUITABLE FOR DYEING POLYESTERS | BASF AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3974123-A | Dyes for thermoplastics | BASF AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3950321-A | POLYESTERS | BASF AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297222-B2 | CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker | MSR1, CD209, M6PR | ALDH1A1 3769/4885MAPT 3666/4885RAB9A 1417/4885 |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1357/4885MAPT 4623/4885RAB9A 1174/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1357/4885MAPT 4623/4885RAB9A 1174/4885 |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | APP, PARK7, IAPP | ALDH1A1 590/4885MAPT 9/4885RAB9A 1184/4885 |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | ALDH1A1 3894/4885MAPT 1938/4885RAB9A 1982/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | ALDH1A1 3894/4885MAPT 1938/4885RAB9A 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.